Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Antipsychotic Roundup 2006 (February) | 2006

View Archived Issues

The CATIE Trial: The Story is in the Dosing

February 1, 2006

Few clinical trials have ever generated as much buzz as the series of trials known as CATIE. CATIE stands for “Clinical Antipsychotic Trials of Intervention Effectiveness,” and is the only set of trials ever done comparing the major second-generation antipsychotics. And because CATIE is funded entirely by NIMH, its results are thought to be quite trustworthy (NEJM 2005;353:1209-1223). Read More

Typical Antipsychotics: A Brief Review

February 1, 2006

Those of us who completed residency anytime during the last 10 years were indoctrinated against the use of conventional neuroleptics because of their array of side effects, particularly extrapyramidal syndromes (EPS) and tardive dyskinesia (TD). Read More

Background of the CATIE Trial

February 1, 2006

John Hsiao, MD

Dr. Hsiao, you were NIMH’s project officer for the CATIE trial. What was your goal when you came up with the idea for CATIE? Read More

What is an “atypical”?

February 1, 2006

Following the introduction of the first neuroleptics in the 1950s, pharmaceutical companies continued screening compounds for psychoactive properties. In 1959, at Wander Laboratories (ultimately purchased by Sandoz), researchers were surprised to discover a chemical similar to tricyclic antidepressants that had antipsychotic properties. They named it clozapine. Read More